Search

everythinglearnresearchcommunity

for

Search:↓

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Cancer treatments often cause skin, nail, and hair problems.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Nilotinib can cause generalized keratosis pilaris.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

The FDA approved a new Pfizer drug for hair loss in teens.

QLT0267 stops hair follicle cell growth and movement.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Erlotinib can cause hair loss as a side effect.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

BMS-470539 reduces skin fibrosis and inflammation.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Ruxolitinib treatment may cause eyelash growth.